APOA5

APOA5

A gene on chromosome 11q23 that encodes apolipoprotein A-V, a minor apolipoprotein mainly associated with high-density lipoprotein (HDL), less so with VLDL and chylomicrons. It is an important determinant of plasma triglyceride (TG) levels, both stimulating TG hydrolysis by apo-CII lipoprotein lipase and inhibiting VLDL-TG production.
References in periodicals archive ?
MUTATIONS IN APOA5 GENE FOUND TO INCREASE BLOOD TRIGLYCERIDES AND HEART ATTACK RISK
10, 2014 /PRNewswire/ -- A team of investigators from the Broad Institute, Massachusetts General Hospital and other leading biomedical research institutions has pinpointed rare mutations in a gene called APOA5 that increase a person's risk of having a heart attack early in life.
Finally, participants were genotyped for 3 polymorphisms in TRIB1 (tribbles pseudokinase 1) (rs2954029), GCKR [glucokinase (hexokinase 4) regulator] (rs1260326), and APOA5 (apolipoprotein A-V) (rs651821) that also reduce plasma nonfasting triglycerides (13), and these were included in sensitivity analyses.
In analyses using CRP, TRIB1, GCKR, and APOA5 genotypes, the analytical strategy was similar.
The study, which was published in the Journal of Lipid Research, sought to appraise the relationship of carriers of variants of the APOA5 gene to atherosclerosis, or hardening of the arteries.
The researchers found that among 2,273 Framingham Offspring Study participants, those who had a particular variant of APOA5 had higher levels of arterial plaque, as measured by carotid artery lining thickness.
Collaborating with Roberto Elosua and Chao Qiang Lai, he appraised the relationship of carriers of variants of the APOA5 gene to atherosclerosis, or hardening of the arteries.
The associations of CHD and stroke with the--1131T>C promoter polymorphism of the APOA5 (apolipoprotein A-V) gene, which is the chief genetic determinant of triglyceride concentrations, were assessed.
3] Human genes: MTHFR, methylenetetrahydrofolate reductase (NAD(P)H); APOA5, apolipoprotein A-V.
The role of APOA5 in regulating TG metabolism has been convincingly demonstrated in animal models (8) and in a large number of association studies (9), in which the -1131T [right arrow] C is the commonly used variant.
Contribution of APOA5 gene variants to plasma triglyceride determination and to the response to both fat and glucose tolerance challenges.
Genetic variation in APOA5 has been consistently associated with plasma triglyceride concentrations in several studies (2-4).